AdaptHealth (NASDAQ:AHCO) & Amedisys (NASDAQ:AMED) Financial Contrast

Amedisys (NASDAQ:AMED) and AdaptHealth (NASDAQ:AHCO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations.

Earnings and Valuation

This table compares Amedisys and AdaptHealth’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amedisys $1.96 billion 3.94 $126.83 million $4.40 54.00
AdaptHealth $529.64 million 3.67 -$15.00 million $0.30 76.77

Amedisys has higher revenue and earnings than AdaptHealth. Amedisys is trading at a lower price-to-earnings ratio than AdaptHealth, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Amedisys and AdaptHealth, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amedisys 0 3 11 0 2.79
AdaptHealth 0 0 6 0 3.00

Amedisys currently has a consensus price target of $236.21, indicating a potential downside of 0.58%. AdaptHealth has a consensus price target of $24.33, indicating a potential upside of 5.66%. Given AdaptHealth’s stronger consensus rating and higher possible upside, analysts plainly believe AdaptHealth is more favorable than Amedisys.

Risk and Volatility

Amedisys has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, AdaptHealth has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500.

Profitability

This table compares Amedisys and AdaptHealth’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amedisys 6.50% 22.41% 10.67%
AdaptHealth N/A -42.67% 1.17%

Institutional & Insider Ownership

89.7% of Amedisys shares are owned by institutional investors. Comparatively, 12.4% of AdaptHealth shares are owned by institutional investors. 2.8% of Amedisys shares are owned by insiders. Comparatively, 10.9% of AdaptHealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Amedisys beats AdaptHealth on 10 of the 14 factors compared between the two stocks.

About Amedisys

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2019, the company owned and operated 472 care centers in 38 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.

About AdaptHealth

AdaptHealth, LLC distributes home medical equipment. The Company offers mobility products, respiratory therapy, non- invasive ventilation, nutrition supplies, ocean home health products, sleep therapy supplies, bed lifts, seat lift chairs, and bath aids. AdaptHealth, LLC was founded in 2012 and is based in Phoenixville, Pennsylvania.

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.